Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation Kellie A. Juradoa, Hao Wanga, Alison Slaughterb, Lei Fengb, Jacques J. Kesslb, Yasuhiro Koha, Weifeng Wanga, Alliso

Source URL: engelmanlab.med.harvard.edu

June 17, 2009  Chemicals Targeting an HIV‐1 Nef/Host Cell Kinase Complex as Novel Anti‐ Retroviral Compounds    Damilola A. Adepegba, Department of Natural Sciences, University of Maryland 

Source URL: www.csb.pitt.edu

• Microbiology
• HIV/AIDS
• Virology
• Integrase
• HIV
• Nef
• Management of HIV/AIDS
• Zidovudine
• Retrovirus
• Discovery and development of integrase inhibitors
• Discovery and development of HIV-protease inhibitors

Title Authors Affiliations

Source URL: www.csb.pitt.edu

• Tyrosine kinases
• Microbiology
• HIV/AIDS
• Virology
• Nef
• HCK
• HIV
• Integrase
• Tyrosine-protein kinase CSK
• Src family kinase
• Proto-oncogene tyrosine-protein kinase Src
• Zidovudine

GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a reasonable testing program, the product referenced in this certificate complies with applicable regulations

Source URL: gilead.com

• Organofluorides
• Pharmacology
• Integrase inhibitors
• Tenofovir
• Emtricitabine
• Gilead
• Cobicistat
• Elvitegravir
• GS
• Gilead Sciences
• Chemistry
• Organic chemistry

Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav

Source URL: shionogi616.tew-staging.com

• Intel Viiv
• Integrase inhibitors
• Organofluorides
• Pfizer
• Biology
• Pharmacology
• Dolutegravir
• Shionogi
• Pharmaceutical industry
• Pharmaceutical sciences
• ViiV Healthcare
• GlaxoSmithKline

Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S

Source URL: shionogi616.tew-staging.com

• Medicine
• HIV/AIDS
• Cyclopropanes
• Integrase inhibitors
• Amides
• Lamivudine
• Zidovudine
• Antiretroviral drug
• GlaxoSmithKline
• Chemistry
• Organic chemistry
• Organofluorides

  Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir  in Treatment‐Naïve Adults with HIV‐1    

Source URL: shionogi616.tew-staging.com

• Organic chemistry
• Health
• HIV/AIDS
• Amides
• Oxadiazoles
• Raltegravir
• Lamivudine
• GlaxoSmithKline
• Dolutegravir
• Organofluorides
• Chemistry
• Integrase inhibitors

Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I

Source URL: shionogi616.tew-staging.com

• Sulfonamides
• Medicine
• Carbamates
• Darunavir
• HIV/AIDS
• Antiretroviral drug
• ViiV Healthcare
• Zidovudine
• Integrase inhibitor
• Protease inhibitors
• Chemistry
• Biology

Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside

Source URL: shionogi616.tew-staging.com

• Organic chemistry
• Medicine
• Amides
• Merck
• Oxadiazoles
• Raltegravir
• Integrase
• Dolutegravir
• ViiV Healthcare
• Integrase inhibitors
• Chemistry
• Organofluorides

ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P

Source URL: shionogi616.tew-staging.com

• Integrase inhibitors
• Abacavir
• Cyclopropanes
• Purines
• Antiretroviral drug
• HIV/AIDS
• Lamivudine
• Reverse-transcriptase inhibitor
• ViiV Healthcare
• Biology
• Chemistry
• Organofluorides